ConductScience.org, home

Paper1361080

New antimetabolites in the treatment of human malignancies.

Cheson BD. Semin Oncol, 1992. Cited by 53 papers, by iCite.

Cite this record

ConductScience Library. New antimetabolites in the treatment of human malignancies. Papers, record 1361080. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/1361080

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
New antimetabolites in the treatment of human malignancies.
PubMed
Journal
Semin Oncol
PubMed
Year
1992
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
53
iCite
Relative citation ratio, by iCite
1.51
iCite
Revised in PubMed
2021-12-03
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Cheson BDB D

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antimetabolites, AntineoplasticMajor topic
Drugs, InvestigationalMajor topic
Animals
Cladribine
Clinical Trials as Topic
Forecasting
Humans
Immunosuppression Therapy
Leukemia
Lymphoma
Pentostatin
Purines
Vidarabine

Source PubMed

Download CSV of topics

Cited by10

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 53 citations.

PMIDTitleJournalYearIn PapersSource
36077112SHMT2 Induces Stemness and Progression of Head and Neck Cancer.Int J Mol Sci2022https://conductscience.org/library/papers/36077112PubMed
34836965Quinacrine-CASIN combination overcomes chemoresistance in human acute lymphoid leukemia.Nat Commun2021https://conductscience.org/library/papers/34836965PubMed
23822983Serine, glycine and one-carbon units: cancer metabolism in full circle.Nat Rev Cancer2013https://conductscience.org/library/papers/23822983PubMed
19476376Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer.Chem Rev2009https://conductscience.org/library/papers/19476376PubMed
19048119Resistance to cytarabine induces the up-regulation of NKG2D ligands and enhances natural killer cell lysis of leukemic cells.Neoplasia2008https://conductscience.org/library/papers/19048119PubMed
11417472Nucleoside analogues: mechanisms of drug resistance and reversal strategies.Leukemia2001https://conductscience.org/library/papers/11417472PubMed
10733261Management of chronic lymphocytic leukaemia.Drugs Aging2000https://conductscience.org/library/papers/10733261PubMed
8601570Current concepts of treatment in medical oncology: new anticancer drugs.J Cancer Res Clin Oncol1996https://conductscience.org/library/papers/8601570PubMed
8137458Pharmacokinetics of the anticancer agent 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine in rats.Cancer Chemother Pharmacol1994https://conductscience.org/library/papers/8137458PubMed
7948311Clinical and toxicological aspects of the antineoplastic drug cladribine: a review.Ann Hematol1994https://conductscience.org/library/papers/7948311PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/1361080

GET https://conductscience.org/api/papers/v1/1361080/authors